Phthalates Exposure in Type 2 Diabetic Patients and Diuretic Therapy
Status:
Active, not recruiting
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
In this open clinical trial, 30 subjects with inadequately controlled T2D and eligible, as
per good clinical practice, for therapy with SGLT-2 inhibitor, will be randomized to receive
a SGLT-2 inhibitor vs other oral-antidiabetic drugs (OADs) therapy for 3 months. Measures
will be performed at baseline, after 2 days, after one month and at the end of the study
protocol, as per good clinical practice